A useful therapy for this leukemia has been derived from an inhibitor of Bruton’s tyrosine kinase: ibrutinib, which blocks essential signaling in CLL cell activation, including the inside-out signaling linking B-cell membrane receptors and chemokine receptors to activation of LFA-1. Here, ITGB2 is linked to leukemia.